168 related articles for article (PubMed ID: 38475660)
21. Identification and validation of ferroptosis-related lncRNA signature as a prognostic model for skin cutaneous melanoma.
Guo S; Chen J; Yi X; Lu Z; Guo W
Front Immunol; 2022; 13():985051. PubMed ID: 36248853
[TBL] [Abstract][Full Text] [Related]
22. DNA methylation-related lncRNAs predict prognosis and immunotherapy response in gastric cancer.
Guo X; Wang Y; Zha L; Li H; Qian K
J Cancer Res Clin Oncol; 2023 Nov; 149(16):14745-14760. PubMed ID: 37592033
[TBL] [Abstract][Full Text] [Related]
23. Machine learning-based tumor-infiltrating immune cell-associated lncRNAs for predicting prognosis and immunotherapy response in patients with glioblastoma.
Zhang H; Zhang N; Wu W; Zhou R; Li S; Wang Z; Dai Z; Zhang L; Liu Z; Zhang J; Luo P; Liu Z; Cheng Q
Brief Bioinform; 2022 Nov; 23(6):. PubMed ID: 36136350
[TBL] [Abstract][Full Text] [Related]
24. A novel endoplasmic reticulum stress-related lncRNA signature for prognosis prediction and immune response evaluation in Stomach adenocarcinoma.
Song Z; Su M; Li X; Xie J; Han F; Yao J
BMC Gastroenterol; 2023 Dec; 23(1):432. PubMed ID: 38066437
[TBL] [Abstract][Full Text] [Related]
25. A novel pyroptosis-related LncRNA signature predicts prognosis and indicates tumor immune microenvironment in skin cutaneous melanoma.
Zhong J; Wang Z; Houssou Hounye A; Liu J; Zhang J; Qi M
Life Sci; 2022 Oct; 307():120832. PubMed ID: 35940218
[TBL] [Abstract][Full Text] [Related]
26. The fatty acid-related gene signature stratifies poor prognosis patients and characterizes TIME in cutaneous melanoma.
Hua S; Wang W; Yao Z; Gu J; Zhang H; Zhu J; Xie Z; Jiang H
J Cancer Res Clin Oncol; 2024 Jan; 150(2):40. PubMed ID: 38279987
[TBL] [Abstract][Full Text] [Related]
27. Identification and characterization of a 25-lncRNA prognostic signature for early recurrence in hepatocellular carcinoma.
Fu Y; Wei X; Han Q; Le J; Ma Y; Lin X; Xu Y; Liu N; Wang X; Kong X; Gu J; Tong Y; Wu H
BMC Cancer; 2021 Oct; 21(1):1165. PubMed ID: 34717566
[TBL] [Abstract][Full Text] [Related]
28. Core immune cell infiltration signatures identify molecular subtypes and promote precise checkpoint immunotherapy in cutaneous melanoma.
Zhu Z; Li G; Li Z; Wu Y; Yang Y; Wang M; Zhang H; Qu H; Song Z; He Y
Front Immunol; 2022; 13():914612. PubMed ID: 36072600
[TBL] [Abstract][Full Text] [Related]
29. DNA damage repair-related gene signature predicts prognosis and indicates immune cell infiltration landscape in skin cutaneous melanoma.
Liang L; Mai S; Mai G; Chen Y; Liu L
Front Endocrinol (Lausanne); 2022; 13():882431. PubMed ID: 35957812
[TBL] [Abstract][Full Text] [Related]
30. A novel copper-induced cell death-related lncRNA prognostic signature associated with immune infiltration and clinical value in gastric cancer.
Wang L; Xiao K; Dong Z; Meng T; Cheng X; Xu Y
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10543-10559. PubMed ID: 37291405
[TBL] [Abstract][Full Text] [Related]
31. The development and experimental validation of hypoxia-related long noncoding RNAs prognostic signature in predicting prognosis and immunotherapy of cutaneous melanoma.
Wang G; Sun Y; Xu Q
Aging (Albany NY); 2023 Nov; 15(21):11918-11939. PubMed ID: 37921852
[TBL] [Abstract][Full Text] [Related]
32. Immunogenic cell death-related long noncoding RNA influences immunotherapy against lung adenocarcinoma.
Sun D; Zhang C
Oncol Res; 2023; 31(5):753-767. PubMed ID: 37547766
[TBL] [Abstract][Full Text] [Related]
33. Identification of hub gene and lncRNA signature related to entotic cell death in cutaneous melanoma for prognostic and immune prediction.
Zhang C; Shen C
Medicine (Baltimore); 2023 Nov; 102(45):e35881. PubMed ID: 37960805
[TBL] [Abstract][Full Text] [Related]
34. A six-long non-coding RNA signature predicts prognosis in melanoma patients.
Yang S; Xu J; Zeng X
Int J Oncol; 2018 Apr; 52(4):1178-1188. PubMed ID: 29436619
[TBL] [Abstract][Full Text] [Related]
35. An exosome-derived lncRNA signature identified by machine learning associated with prognosis and biomarkers for immunotherapy in ovarian cancer.
Cui Y; Zhang W; Lu W; Feng Y; Wu X; Zhuo Z; Zhang D; Zhang Y
Front Immunol; 2024; 15():1228235. PubMed ID: 38404588
[TBL] [Abstract][Full Text] [Related]
36. Identification of EMT-associated LncRNA Signature for Predicting the Prognosis of Patients with Endometrial Cancer.
Shu W; Wang Z; Zhang W; Zhang J; Zhao R; Yu Z; Dong K; Wang H
Comb Chem High Throughput Screen; 2023; 26(8):1488-1502. PubMed ID: 36200154
[TBL] [Abstract][Full Text] [Related]
37. Novel cuproptosis-related long non-coding RNA signature to predict prognosis in prostate carcinoma.
Cheng X; Zeng Z; Yang H; Chen Y; Liu Y; Zhou X; Zhang C; Wang G
BMC Cancer; 2023 Jan; 23(1):105. PubMed ID: 36717792
[TBL] [Abstract][Full Text] [Related]
38. Pyroptosis-related lncRNA prognostic signatures for cutaneous melanoma and tumor microenvironment status.
Deng H; Chen Y; An R; Wang J
Epigenomics; 2023 Jun; 15(12):657-675. PubMed ID: 37577979
[No Abstract] [Full Text] [Related]
39. A Novel m6A-Related LncRNA Signature for Predicting Prognosis, Chemotherapy and Immunotherapy Response in Patients with Lung Adenocarcinoma.
Shen Y; Wang S; Wu Y
Cells; 2022 Aug; 11(15):. PubMed ID: 35954243
[TBL] [Abstract][Full Text] [Related]
40. Computational identification and clinical validation of a novel risk signature based on coagulation-related lncRNAs for predicting prognosis, immunotherapy response, and chemosensitivity in colorectal cancer patients.
Zhang F; Zhang R; Zong J; Hou Y; Zhou M; Yan Z; Li T; Gan W; Lv S; Yang L; Zeng Z; Zhao W; Yang M
Front Immunol; 2023; 14():1279789. PubMed ID: 37928532
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
